S18-453 Chimeric Antigen Receptors Targeting Glycipan-2 Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics. Sabine Heitzeneder Robbie Majzner Crystal Mackall John Maris Kristopher Bosse Dimiter Dimitrov Zhongyu Zhu